Coherus BioSciences Inc
NASDAQ:CHRS

Watchlist Manager
Coherus BioSciences Inc Logo
Coherus BioSciences Inc
NASDAQ:CHRS
Watchlist
Price: 0.8672 USD -0.12% Market Closed
Market Cap: 100.5m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+128%
Revenue
Forecast
+9%
Operating Income
Forecast
+28%
Net Income
Forecast
+161%

Wall Street
Price Targets

CHRS Price Targets Summary
Coherus BioSciences Inc

Wall Street analysts forecast CHRS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CHRS is 4.777 USD with a low forecast of 1.0605 USD and a high forecast of 7.35 USD.

CHRS Lowest Forecast
Wall Street Target
1.0605 USD
22% Upside
CHRS Average Forecast
Wall Street Target
4.777 USD
451% Upside
CHRS Highest Forecast
Wall Street Target
7.35 USD
748% Upside
Lowest
Price Target
1.0605 USD
22% Upside
Average
Price Target
4.777 USD
451% Upside
Highest
Price Target
7.35 USD
748% Upside
Coherus BioSciences Inc Competitors:
Price Targets
HUMA
Humacyte Inc
283% Upside
HPHA
Heidelberg Pharma AG
169% Upside
ATYR
aTyr Pharma Inc
243% Upside
LXRX
Lexicon Pharmaceuticals Inc
133% Upside
HUMA
Humacyte Inc
283% Upside
HPHA
Heidelberg Pharma AG
169% Upside
ATYR
aTyr Pharma Inc
243% Upside
LXRX
Lexicon Pharmaceuticals Inc
133% Upside
1530
3SBio Inc
14% Downside
COV
Covalon Technologies Ltd
49% Upside
BIIB
Biogen Inc
28% Upside
ALNY
Alnylam Pharmaceuticals Inc
3% Upside

Revenue
Forecast

Revenue Estimate
Coherus BioSciences Inc

For the last 8 years the compound annual growth rate for Coherus BioSciences Inc's revenue is 4%. The projected CAGR for the next 3 years is -22%.

4%
Past Growth
-22%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Coherus BioSciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Coherus BioSciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-39%
Average Miss
What are analyst estimates?

See Also

Summary
CHRS intrinsic value, competitors valuation, and company profile.
DCF Valuation
CHRS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CHRS stock valuation using valuation multiples.
Wall Street Estimates
CHRS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CHRS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CHRS's stock price target?
Price Target
4.777 USD

According to Wall Street analysts, the average 1-year price target for CHRS is 4.777 USD with a low forecast of 1.0605 USD and a high forecast of 7.35 USD.

What is Coherus BioSciences Inc's Revenue forecast?
Projected CAGR
-22%

For the last 8 years the compound annual growth rate for Coherus BioSciences Inc's revenue is 4%. The projected CAGR for the next 3 years is -22%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 266,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.